TY - JOUR
T1 - Gut microbiota features associated with campylobacter burden and postnatal linear growth deficits in a peruvian birth cohort
AU - Rouhani, Saba
AU - Griffin, Nicholas W.
AU - Yori, Pablo Peñataro
AU - Olortegui, Maribel Paredes
AU - Salas, Mery Siguas
AU - Trigoso, Dixner Rengifo
AU - Moulton, Lawrence H.
AU - Houpt, Eric R.
AU - Barratt, Michael J.
AU - Kosek, Margaret N.
AU - Gordon, Jeffrey I.
N1 - Publisher Copyright:
© The Author(s) 2019.
PY - 2020/8/15
Y1 - 2020/8/15
N2 - Background. Campylobacter infection is associated with impaired growth of children, even in the absence of symptoms. To examine the underlying mechanisms, we evaluated associations between Campylobacter infection, linear growth, and fecal microbial community features in a prospective birth cohort of 271 children with a high burden of diarrhea and stunting in the Amazonian lowlands of Peru. Methods. Campylobacter was identified using a broadly reactive, genus-specific enzyme-linked immunosorbent assay. 16S rRNAbased analyses were used to identify bacterial taxa in fecal samples at ages 6, 12, 18, and 24 months (N = 928). Associations between infection, growth, and gut microbial community composition were investigated using multiple linear regression adjusting for withinchild correlations, age, and breastfeeding. Indicator species analyses identified taxa specifically associated with Campylobacter burden. Results. Ninety-three percent (251) of children had Campylobacter present in asymptomatic fecal samples during the follow-up period. A 10% increase in the proportion of stools infected was associated with mean reductions of 0.02 length-for-age z scores (LAZ) at 3, 6, and 9 months thereafter (P < .01). We identified 13 bacterial taxa indicative of cumulative Campylobacter burden and 14 taxa significantly associated with high or low burden of enteroaggregative Escherichia coli, norovirus, or Giardia. Conclusions. Campylobacter infection is common in this cohort and associated with changes in microbial community composition. These results support the notion that disruptions to the fecal microbiota may help explain the observed effects of asymptomatic infections on growth in early life.
AB - Background. Campylobacter infection is associated with impaired growth of children, even in the absence of symptoms. To examine the underlying mechanisms, we evaluated associations between Campylobacter infection, linear growth, and fecal microbial community features in a prospective birth cohort of 271 children with a high burden of diarrhea and stunting in the Amazonian lowlands of Peru. Methods. Campylobacter was identified using a broadly reactive, genus-specific enzyme-linked immunosorbent assay. 16S rRNAbased analyses were used to identify bacterial taxa in fecal samples at ages 6, 12, 18, and 24 months (N = 928). Associations between infection, growth, and gut microbial community composition were investigated using multiple linear regression adjusting for withinchild correlations, age, and breastfeeding. Indicator species analyses identified taxa specifically associated with Campylobacter burden. Results. Ninety-three percent (251) of children had Campylobacter present in asymptomatic fecal samples during the follow-up period. A 10% increase in the proportion of stools infected was associated with mean reductions of 0.02 length-for-age z scores (LAZ) at 3, 6, and 9 months thereafter (P < .01). We identified 13 bacterial taxa indicative of cumulative Campylobacter burden and 14 taxa significantly associated with high or low burden of enteroaggregative Escherichia coli, norovirus, or Giardia. Conclusions. Campylobacter infection is common in this cohort and associated with changes in microbial community composition. These results support the notion that disruptions to the fecal microbiota may help explain the observed effects of asymptomatic infections on growth in early life.
KW - Campylobacter
KW - Child growth
KW - Enteropathy
KW - Microbiota
UR - http://www.scopus.com/inward/record.url?scp=85089612493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089612493&partnerID=8YFLogxK
U2 - 10.1093/cid/ciz906
DO - 10.1093/cid/ciz906
M3 - Article
C2 - 31773126
AN - SCOPUS:85089612493
SN - 1058-4838
VL - 71
SP - 1000
EP - 1007
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 4
ER -